Skip to main content
Erschienen in: Zeitschrift für Rheumatologie 3/2020

01.11.2020 | Vaskulitiden | Leitlinien

S2k-Leitlinie: Management der Großgefäßvaskulitiden

verfasst von: Dr. J. H. Schirmer, P. M. Aries, K. Balzer, P. Berlit, T. A. Bley, F. Buttgereit, M. Czihal, C. Dechant, C. Dejaco, U. Garske, J. Henes, J. U. Holle, K. Holl-Ulrich, P. Lamprecht, B. Nölle, F. Moosig, J. Rech, K. Scheuermann, M. Schmalzing, W. A. Schmidt, M. Schneider, H. Schulze-Koops, N. Venhoff, P. M. Villiger, T. Witte, M. Zänker, Prof. Dr. B. Hellmich

Erschienen in: Zeitschrift für Rheumatologie | Sonderheft 3/2020

Einloggen, um Zugang zu erhalten

Auszug

Klassifikation: S2k …
Anhänge
Nur mit Berechtigung zugänglich
Literatur
3.
Zurück zum Zitat Achkar AA, Lie JT, Hunder GG et al (1994) How does previous corticosteroid treatment affect the biopsy findings in giant cell (temporal) arteritis? Ann Intern Med 120:987–992CrossRefPubMed Achkar AA, Lie JT, Hunder GG et al (1994) How does previous corticosteroid treatment affect the biopsy findings in giant cell (temporal) arteritis? Ann Intern Med 120:987–992CrossRefPubMed
9.
11.
Zurück zum Zitat Ando M, Kosakai Y, Okita Y et al (1999) Surgical treatment for aortic regurgitation caused by non-specific aortitis. Cardiovasc Surg 7:409–413CrossRefPubMed Ando M, Kosakai Y, Okita Y et al (1999) Surgical treatment for aortic regurgitation caused by non-specific aortitis. Cardiovasc Surg 7:409–413CrossRefPubMed
12.
Zurück zum Zitat Arend WP, Michel BA, Bloch DA et al (1990) The American College of Rheumatology 1990 criteria for the classification of Takayasu arteritis. Arthritis Rheum 33:1129–1134CrossRefPubMed Arend WP, Michel BA, Bloch DA et al (1990) The American College of Rheumatology 1990 criteria for the classification of Takayasu arteritis. Arthritis Rheum 33:1129–1134CrossRefPubMed
15.
Zurück zum Zitat Aschwanden M, Imfeld S, Staub D et al (2015) The ultrasound compression sign to diagnose temporal giant cell arteritis shows an excellent interobserver agreement. Clin Exp Rheumatol 33:113–115 Aschwanden M, Imfeld S, Staub D et al (2015) The ultrasound compression sign to diagnose temporal giant cell arteritis shows an excellent interobserver agreement. Clin Exp Rheumatol 33:113–115
17.
Zurück zum Zitat Bali HK, Jain S, Jain A, Sharma BK (1998) Stent supported angioplasty in Takayasu arteritis. Int J Cardiol 66(Suppl 1):S213–S217 (discussion S219–S220)CrossRefPubMed Bali HK, Jain S, Jain A, Sharma BK (1998) Stent supported angioplasty in Takayasu arteritis. Int J Cardiol 66(Suppl 1):S213–S217 (discussion S219–S220)CrossRefPubMed
21.
Zurück zum Zitat Berger CT, Greiff V, John S et al (2015) Risk factors for pneumocystis pneumonia in giant cell arteritis: a single-centre cohort study. Clin Exp Rheumatol 33:122–125 Berger CT, Greiff V, John S et al (2015) Risk factors for pneumocystis pneumonia in giant cell arteritis: a single-centre cohort study. Clin Exp Rheumatol 33:122–125
23.
Zurück zum Zitat Berlit P, Krämer M et al (2018) Zerebrale Vaskulitis und zerebrale Beteiligung bei systemischen Vaskulitiden und rheumatischen Grunderkrankungen, S1-Leitlinie in: Deutsche Gesellschaft für Neurologie (Hrsg.), Leitlinien für Diagnostik und Therapie in der Neurologie. www.dgn.org/leitlinien. Zugegriffen: 3. Juni 2019 Berlit P, Krämer M et al (2018) Zerebrale Vaskulitis und zerebrale Beteiligung bei systemischen Vaskulitiden und rheumatischen Grunderkrankungen, S1-Leitlinie in: Deutsche Gesellschaft für Neurologie (Hrsg.), Leitlinien für Diagnostik und Therapie in der Neurologie. www.​dgn.​org/​leitlinien. Zugegriffen: 3. Juni 2019
27.
Zurück zum Zitat Blockmans D, Stroobants S, Maes A, Mortelmans L (2000) Positron emission tomography in giant cell arteritis and polymyalgia rheumatica: evidence for inflammation of the aortic arch. Am J Med 108:246–249CrossRefPubMed Blockmans D, Stroobants S, Maes A, Mortelmans L (2000) Positron emission tomography in giant cell arteritis and polymyalgia rheumatica: evidence for inflammation of the aortic arch. Am J Med 108:246–249CrossRefPubMed
36.
Zurück zum Zitat de Boysson H, Liozon E, Ly KH et al (2019) The different clinical patterns of giant cell arteritis. Clin Exp Rheumatol 37(Suppl 117):57–60PubMed de Boysson H, Liozon E, Ly KH et al (2019) The different clinical patterns of giant cell arteritis. Clin Exp Rheumatol 37(Suppl 117):57–60PubMed
37.
Zurück zum Zitat Breuer GS, Nesher R, Reinus K, Nesher G (2013) Association between histological features in temporal artery biopsies and clinical features of patients with giant cell arteritis. Isr Med Assoc J 15:271–274PubMed Breuer GS, Nesher R, Reinus K, Nesher G (2013) Association between histological features in temporal artery biopsies and clinical features of patients with giant cell arteritis. Isr Med Assoc J 15:271–274PubMed
40.
Zurück zum Zitat Buttgereit F, Brabant T et al (2018) S3 guidelines on treatment of polymyalgia rheumatica: evidence-based guidelines of the German Society of Rheumatology (DGRh), the Austrian Society of Rheumatology and Rehabilitation (ÖGR) and the Swiss Society of Rheumatology (SGT) and participating medical scientific specialist societies and other organizations. Z Rheumatol 77:429–441. https://doi.org/10.1007/s00393-018-0476-8CrossRefPubMed Buttgereit F, Brabant T et al (2018) S3 guidelines on treatment of polymyalgia rheumatica: evidence-based guidelines of the German Society of Rheumatology (DGRh), the Austrian Society of Rheumatology and Rehabilitation (ÖGR) and the Swiss Society of Rheumatology (SGT) and participating medical scientific specialist societies and other organizations. Z Rheumatol 77:429–441. https://​doi.​org/​10.​1007/​s00393-018-0476-8CrossRefPubMed
43.
Zurück zum Zitat Chan CC, Paine M, O’Day J (2001) Steroid management in giant cell arteritis. Br J Ophthalmol 85:1061–1064CrossRefPubMed Chan CC, Paine M, O’Day J (2001) Steroid management in giant cell arteritis. Br J Ophthalmol 85:1061–1064CrossRefPubMed
44.
Zurück zum Zitat Chandran A, Udayakumar PD, Kermani TA et al (2015) Glucocorticoid usage in giant cell arteritis over six decades (1950 to 2009). Clin Exp Rheumatol 33:98–102 Chandran A, Udayakumar PD, Kermani TA et al (2015) Glucocorticoid usage in giant cell arteritis over six decades (1950 to 2009). Clin Exp Rheumatol 33:98–102
47.
Zurück zum Zitat Chevalet P, Barrier JH, Pottier P et al (2000) A randomized, multicenter, controlled trial using intravenous pulses of methylprednisolone in the initial treatment of simple forms of giant cell arteritis: a one year followup study of 164 patients. J Rheumatol 27:1484–1491PubMed Chevalet P, Barrier JH, Pottier P et al (2000) A randomized, multicenter, controlled trial using intravenous pulses of methylprednisolone in the initial treatment of simple forms of giant cell arteritis: a one year followup study of 164 patients. J Rheumatol 27:1484–1491PubMed
49.
Zurück zum Zitat Chung JB, Armstrong K, Schwartz JS, Albert D (2000) Cost-effectiveness of prophylaxis against pneumocystis carinii pneumonia in patients with Wegner’s granulomatosis undergoing immunosuppressive therapy. Arthritis Rheum 43:1841–1848. https://doi.org/10.1002/1529-0131(200008)43:8〈1841::AID-ANR21〉3.0.CO;2‑QCrossRefPubMed Chung JB, Armstrong K, Schwartz JS, Albert D (2000) Cost-effectiveness of prophylaxis against pneumocystis carinii pneumonia in patients with Wegner’s granulomatosis undergoing immunosuppressive therapy. Arthritis Rheum 43:1841–1848. https://​doi.​org/​10.​1002/​1529-0131(200008)43:8〈1841::AID-ANR21〉3.0.CO;2‑QCrossRefPubMed
61.
Zurück zum Zitat De Silva M, Hazleman BL (1986) Azathioprine in giant cell arteritis/polymyalgia rheumatica: a double-blind study. Ann Rheum Dis 45:136–138CrossRefPubMed De Silva M, Hazleman BL (1986) Azathioprine in giant cell arteritis/polymyalgia rheumatica: a double-blind study. Ann Rheum Dis 45:136–138CrossRefPubMed
65.
Zurück zum Zitat Delecoeuillerie G, Joly P, Cohen de Lara A, Paolaggi JB (1988) Polymyalgia rheumatica and temporal arteritis: a retrospective analysis of prognostic features and different corticosteroid regimens (11 year survey of 210 patients). Ann Rheum Dis 47:733–739CrossRefPubMed Delecoeuillerie G, Joly P, Cohen de Lara A, Paolaggi JB (1988) Polymyalgia rheumatica and temporal arteritis: a retrospective analysis of prognostic features and different corticosteroid regimens (11 year survey of 210 patients). Ann Rheum Dis 47:733–739CrossRefPubMed
67.
Zurück zum Zitat Diamantopoulos AP, Haugeberg G, Hetland H et al (2014) Diagnostic value of color Doppler ultrasonography of temporal arteries and large vessels in giant cell arteritis: a consecutive case series. Arthritis Care Res 66:113–119. https://doi.org/10.1002/acr.22178CrossRef Diamantopoulos AP, Haugeberg G, Hetland H et al (2014) Diagnostic value of color Doppler ultrasonography of temporal arteries and large vessels in giant cell arteritis: a consecutive case series. Arthritis Care Res 66:113–119. https://​doi.​org/​10.​1002/​acr.​22178CrossRef
68.
Zurück zum Zitat Diamantopoulos AP, Haugeberg G, Lindland A, Myklebust G (2016) The fast-track ultrasound clinic for early diagnosis of giant cell arteritis significantly reduces permanent visual impairment: towards a more effective strategy to improve clinical outcome in giant cell arteritis? Rheumatology (Oxford) 55:66–70. https://doi.org/10.1093/rheumatology/kev289CrossRef Diamantopoulos AP, Haugeberg G, Lindland A, Myklebust G (2016) The fast-track ultrasound clinic for early diagnosis of giant cell arteritis significantly reduces permanent visual impairment: towards a more effective strategy to improve clinical outcome in giant cell arteritis? Rheumatology (Oxford) 55:66–70. https://​doi.​org/​10.​1093/​rheumatology/​kev289CrossRef
69.
Zurück zum Zitat Dong H, Che W, Jiang X et al (2017) An unrecognised presentation of Takayasu arteritis: superficial femoral artery involvement. Clin Exp Rheumatol 35(Suppl 103):83–87PubMed Dong H, Che W, Jiang X et al (2017) An unrecognised presentation of Takayasu arteritis: superficial femoral artery involvement. Clin Exp Rheumatol 35(Suppl 103):83–87PubMed
74.
Zurück zum Zitat Erbel R, Aboyans V, Boileau C et al (2014) 2014 ESC Guidelines on the diagnosis and treatment of aortic diseases: document covering acute and chronic aortic diseases of the thoracic and abdominal aorta of the adult. The Task Force for the Diagnosis and Treatment of Aortic Diseases of the European Society of Cardiology (ESC). Eur Heart J 35:2873–2926. https://doi.org/10.1093/eurheartj/ehu281CrossRefPubMed Erbel R, Aboyans V, Boileau C et al (2014) 2014 ESC Guidelines on the diagnosis and treatment of aortic diseases: document covering acute and chronic aortic diseases of the thoracic and abdominal aorta of the adult. The Task Force for the Diagnosis and Treatment of Aortic Diseases of the European Society of Cardiology (ESC). Eur Heart J 35:2873–2926. https://​doi.​org/​10.​1093/​eurheartj/​ehu281CrossRefPubMed
77.
Zurück zum Zitat Evans JM, O’Fallon WM, Hunder GG (1995) Increased incidence of aortic aneurysm and dissection in giant cell (temporal) arteritis. A population-based study. Ann Intern Med 122:502–507CrossRefPubMed Evans JM, O’Fallon WM, Hunder GG (1995) Increased incidence of aortic aneurysm and dissection in giant cell (temporal) arteritis. A population-based study. Ann Intern Med 122:502–507CrossRefPubMed
83.
Zurück zum Zitat Germanò G, Macchioni P, Possemato N et al (2017) Contrast-enhanced ultrasound of the carotid artery in patients with large vessel vasculitis: correlation with positron emission tomography findings. Arthritis Care Res 69:143–149. https://doi.org/10.1002/acr.22906CrossRef Germanò G, Macchioni P, Possemato N et al (2017) Contrast-enhanced ultrasound of the carotid artery in patients with large vessel vasculitis: correlation with positron emission tomography findings. Arthritis Care Res 69:143–149. https://​doi.​org/​10.​1002/​acr.​22906CrossRef
88.
Zurück zum Zitat González-Gay MA, Blanco R, Rodríguez-Valverde V et al (1998) Permanent visual loss and cerebrovascular accidents in giant cell arteritis: predictors and response to treatment. Arthritis Rheum 41:1497–1504. https://doi.org/10.1002/1529-0131(199808)41:8〈1497::AID-ART22〉3.0.CO;2‑ZCrossRefPubMed González-Gay MA, Blanco R, Rodríguez-Valverde V et al (1998) Permanent visual loss and cerebrovascular accidents in giant cell arteritis: predictors and response to treatment. Arthritis Rheum 41:1497–1504. https://​doi.​org/​10.​1002/​1529-0131(199808)41:8〈1497::AID-ART22〉3.0.CO;2‑ZCrossRefPubMed
91.
Zurück zum Zitat Graham E, Holland A, Avery A, Russell RW (1981) Prognosis in giant-cell arteritis. Br Med J 282:269–271CrossRef Graham E, Holland A, Avery A, Russell RW (1981) Prognosis in giant-cell arteritis. Br Med J 282:269–271CrossRef
92.
93.
Zurück zum Zitat Grossman C, Barshack I, Koren-Morag N et al (2017) Risk factors for severe cranial ischaemic events in patients with giant cell arteritis. Clin Exp Rheumatol 35(Suppl 103):88–93PubMed Grossman C, Barshack I, Koren-Morag N et al (2017) Risk factors for severe cranial ischaemic events in patients with giant cell arteritis. Clin Exp Rheumatol 35(Suppl 103):88–93PubMed
96.
Zurück zum Zitat Hachulla E, Boivin V, Pasturel-Michon U et al (2001) Prognostic factors and long-term evolution in a cohort of 133 patients with giant cell arteritis. Clin Exp Rheumatol 19:171–176PubMed Hachulla E, Boivin V, Pasturel-Michon U et al (2001) Prognostic factors and long-term evolution in a cohort of 133 patients with giant cell arteritis. Clin Exp Rheumatol 19:171–176PubMed
100.
Zurück zum Zitat Hayreh SS, Zimmerman B, Kardon RH (2002) Visual improvement with corticosteroid therapy in giant cell arteritis. Report of a large study and review of literature. Acta Ophthalmol Scand 80:355–367CrossRefPubMed Hayreh SS, Zimmerman B, Kardon RH (2002) Visual improvement with corticosteroid therapy in giant cell arteritis. Report of a large study and review of literature. Acta Ophthalmol Scand 80:355–367CrossRefPubMed
105.
Zurück zum Zitat Hernández-Rodríguez J, García-Martínez A, Casademont J et al (2002) A strong initial systemic inflammatory response is associated with higher corticosteroid requirements and longer duration of therapy in patients with giant-cell arteritis. Arthritis Rheum 47:29–35CrossRefPubMed Hernández-Rodríguez J, García-Martínez A, Casademont J et al (2002) A strong initial systemic inflammatory response is associated with higher corticosteroid requirements and longer duration of therapy in patients with giant-cell arteritis. Arthritis Rheum 47:29–35CrossRefPubMed
107.
Zurück zum Zitat Hernández-Rodríguez J, Tan CD, Rodríguez ER, Hoffman GS (2009) Gynecologic vasculitis: an analysis of 163 patients. Medicine (Baltimore) 88:169–181. https://doi.org/10.1097/MD.0b013e3181a577 f3CrossRef Hernández-Rodríguez J, Tan CD, Rodríguez ER, Hoffman GS (2009) Gynecologic vasculitis: an analysis of 163 patients. Medicine (Baltimore) 88:169–181. https://​doi.​org/​10.​1097/​MD.​0b013e3181a577 f3CrossRef
112.
Zurück zum Zitat Hoffman GS, Cid MC, Rendt-Zagar KE et al (2007) Infliximab for maintenance of glucocorticosteroid-induced remission of giant cell arteritis: a randomized trial. Ann Intern Med 146:621–630CrossRefPubMed Hoffman GS, Cid MC, Rendt-Zagar KE et al (2007) Infliximab for maintenance of glucocorticosteroid-induced remission of giant cell arteritis: a randomized trial. Ann Intern Med 146:621–630CrossRefPubMed
113.
Zurück zum Zitat Hoffman GS, Leavitt RY, Kerr GS et al (1994) Treatment of glucocorticoid-resistant or relapsing Takayasu arteritis with methotrexate. Arthritis Rheum 37:578–582CrossRefPubMed Hoffman GS, Leavitt RY, Kerr GS et al (1994) Treatment of glucocorticoid-resistant or relapsing Takayasu arteritis with methotrexate. Arthritis Rheum 37:578–582CrossRefPubMed
117.
Zurück zum Zitat Hunder GG, Bloch DA, Michel BA et al (1990) The American College of Rheumatology 1990 criteria for the classification of giant cell arteritis. Arthritis Rheum 33:1122–1128CrossRefPubMed Hunder GG, Bloch DA, Michel BA et al (1990) The American College of Rheumatology 1990 criteria for the classification of giant cell arteritis. Arthritis Rheum 33:1122–1128CrossRefPubMed
118.
Zurück zum Zitat Hunder GG, Sheps SG, Allen GL, Joyce JW (1975) Daily and alternate-day corticosteroid regimens in treatment of giant cell arteritis: comparison in a prospective study. Ann Intern Med 82:613–618CrossRefPubMed Hunder GG, Sheps SG, Allen GL, Joyce JW (1975) Daily and alternate-day corticosteroid regimens in treatment of giant cell arteritis: comparison in a prospective study. Ann Intern Med 82:613–618CrossRefPubMed
119.
Zurück zum Zitat Ishikawa K (1988) Diagnostic approach and proposed criteria for the clinical diagnosis of Takayasu’s arteriopathy. J Am Coll Cardiol 12:964–972CrossRefPubMed Ishikawa K (1988) Diagnostic approach and proposed criteria for the clinical diagnosis of Takayasu’s arteriopathy. J Am Coll Cardiol 12:964–972CrossRefPubMed
125.
Zurück zum Zitat Jover JA, Hernández-García C, Morado IC et al (2001) Combined treatment of giant-cell arteritis with methotrexate and prednisone. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 134:106–114CrossRefPubMed Jover JA, Hernández-García C, Morado IC et al (2001) Combined treatment of giant-cell arteritis with methotrexate and prednisone. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 134:106–114CrossRefPubMed
127.
Zurück zum Zitat Kaiser M, Weyand CM, Björnsson J, Goronzy JJ (1998) Platelet-derived growth factor, intimal hyperplasia, and ischemic complications in giant cell arteritis. Arthritis Rheum 41:623–633. https://doi.org//10.1002/1529-0131(199804)41:4〈623::AID-ART9〉3.0.CO;2‑6CrossRefPubMed Kaiser M, Weyand CM, Björnsson J, Goronzy JJ (1998) Platelet-derived growth factor, intimal hyperplasia, and ischemic complications in giant cell arteritis. Arthritis Rheum 41:623–633. https://​doi.​org/​/​10.​1002/​1529-0131(199804)41:4〈623::AID-ART9〉3.0.CO;2‑6CrossRefPubMed
128.
Zurück zum Zitat Karahaliou M, Vaiopoulos G, Papaspyrou S et al (2006) Colour duplex sonography of temporal arteries before decision for biopsy: a prospective study in 55 patients with suspected giant cell arteritis. Arthritis Res Ther 8:R116. https://doi.org/10.1186/ar2003CrossRefPubMed Karahaliou M, Vaiopoulos G, Papaspyrou S et al (2006) Colour duplex sonography of temporal arteries before decision for biopsy: a prospective study in 55 patients with suspected giant cell arteritis. Arthritis Res Ther 8:R116. https://​doi.​org/​10.​1186/​ar2003CrossRefPubMed
138.
Zurück zum Zitat Kobayashi Y, Ishii T, Harigae H (2014) Takayasu’s arteritis. In: Ball GV, Fessler BJ, Bridges SL (Hrsg) Oxf. Textb. Vasc., 3. Aufl. Oxford University Press, Oxford, S 319–329CrossRef Kobayashi Y, Ishii T, Harigae H (2014) Takayasu’s arteritis. In: Ball GV, Fessler BJ, Bridges SL (Hrsg) Oxf. Textb. Vasc., 3. Aufl. Oxford University Press, Oxford, S 319–329CrossRef
141.
Zurück zum Zitat Kyle V, Hazleman BL (1989) Treatment of polymyalgia rheumatica and giant cell arteritis. I. Steroid regimens in the first two months. Ann Rheum Dis 48:658–661CrossRefPubMed Kyle V, Hazleman BL (1989) Treatment of polymyalgia rheumatica and giant cell arteritis. I. Steroid regimens in the first two months. Ann Rheum Dis 48:658–661CrossRefPubMed
150.
Zurück zum Zitat Leon L, Rodriguez-Rodriguez L, Morado I et al (2018) Treatment with methotrexate and risk of relapses in patients with giant cell arteritis in clinical practice. Clin Exp Rheumatol 36(Suppl 111):121–128PubMed Leon L, Rodriguez-Rodriguez L, Morado I et al (2018) Treatment with methotrexate and risk of relapses in patients with giant cell arteritis in clinical practice. Clin Exp Rheumatol 36(Suppl 111):121–128PubMed
151.
Zurück zum Zitat Les I, Pijoán JI, Rodríguez-Álvarez R et al (2015) Effectiveness and safety of medium-dose prednisone in giant cell arteritis: a retrospective cohort study of 103 patients. Clin Exp Rheumatol 33:90–97 Les I, Pijoán JI, Rodríguez-Álvarez R et al (2015) Effectiveness and safety of medium-dose prednisone in giant cell arteritis: a retrospective cohort study of 103 patients. Clin Exp Rheumatol 33:90–97
154.
Zurück zum Zitat Liozon E, Roblot P, Paire D et al (2000) Anticardiolipin antibody levels predict flares and relapses in patients with giant-cell (temporal) arteritis. A longitudinal study of 58 biopsy-proven cases. Rheumatology (Oxford) 39:1089–1094CrossRef Liozon E, Roblot P, Paire D et al (2000) Anticardiolipin antibody levels predict flares and relapses in patients with giant-cell (temporal) arteritis. A longitudinal study of 58 biopsy-proven cases. Rheumatology (Oxford) 39:1089–1094CrossRef
155.
Zurück zum Zitat Loock J, Henes J, Kötter I et al (2012) Treatment of refractory giant cell arteritis with cyclophosphamide: a retrospective analysis of 35 patients from three centres. Clin Exp Rheumatol 30:S70–S76PubMed Loock J, Henes J, Kötter I et al (2012) Treatment of refractory giant cell arteritis with cyclophosphamide: a retrospective analysis of 35 patients from three centres. Clin Exp Rheumatol 30:S70–S76PubMed
159.
Zurück zum Zitat Luqmani R, Lee E, Singh S et al (2016) The role of ultrasound compared to biopsy of temporal arteries in the diagnosis and treatment of giant cell Arteritis (TABUL): a diagnostic accuracy and cost-effectiveness study. Health Technol Assess 20:1–238. https://doi.org/10.3310/hta20900CrossRefPubMed Luqmani R, Lee E, Singh S et al (2016) The role of ultrasound compared to biopsy of temporal arteries in the diagnosis and treatment of giant cell Arteritis (TABUL): a diagnostic accuracy and cost-effectiveness study. Health Technol Assess 20:1–238. https://​doi.​org/​10.​3310/​hta20900CrossRefPubMed
172.
176.
Zurück zum Zitat Miller DV, Maleszewski JJ (2011) The pathology of large-vessel vasculitides. Clin Exp Rheumatol 29:S92–98PubMed Miller DV, Maleszewski JJ (2011) The pathology of large-vessel vasculitides. Clin Exp Rheumatol 29:S92–98PubMed
185.
187.
Zurück zum Zitat Nakaoka Y, Higuchi K, Arita Y et al (2013) Tocilizumab for the treatment of patients with refractory Takayasu arteritis. Int Heart J 54:405–411CrossRefPubMed Nakaoka Y, Higuchi K, Arita Y et al (2013) Tocilizumab for the treatment of patients with refractory Takayasu arteritis. Int Heart J 54:405–411CrossRefPubMed
189.
Zurück zum Zitat Narváez J, Bernad B, Gómez-Vaquero C et al (2008) Impact of antiplatelet therapy in the development of severe ischemic complications and in the outcome of patients with giant cell arteritis. Clin Exp Rheumatol 26:S57–S62PubMed Narváez J, Bernad B, Gómez-Vaquero C et al (2008) Impact of antiplatelet therapy in the development of severe ischemic complications and in the outcome of patients with giant cell arteritis. Clin Exp Rheumatol 26:S57–S62PubMed
193.
Zurück zum Zitat Nesher G, Nesher R, Mates M et al (2008) Giant cell arteritis: intensity of the initial systemic inflammatory response and the course of the disease. Clin Exp Rheumatol 26:S30–S34PubMed Nesher G, Nesher R, Mates M et al (2008) Giant cell arteritis: intensity of the initial systemic inflammatory response and the course of the disease. Clin Exp Rheumatol 26:S30–S34PubMed
195.
196.
199.
Zurück zum Zitat Nunes G, Neves FS, Melo FM et al (2010) Takayasu arteritis: anti-TNF therapy in a Brazilian setting. Rev Bras Reumatol 50:291–298CrossRefPubMed Nunes G, Neves FS, Melo FM et al (2010) Takayasu arteritis: anti-TNF therapy in a Brazilian setting. Rev Bras Reumatol 50:291–298CrossRefPubMed
200.
Zurück zum Zitat Ohigashi H, Haraguchi G, Konishi M et al (2012) Improved prognosis of Takayasu arteritis over the past decade—comprehensive analysis of 106 patients. Circ J 76:1004–1011CrossRefPubMed Ohigashi H, Haraguchi G, Konishi M et al (2012) Improved prognosis of Takayasu arteritis over the past decade—comprehensive analysis of 106 patients. Circ J 76:1004–1011CrossRefPubMed
202.
Zurück zum Zitat Omma A, Erer B, Karadag O et al (2017) Remarkable damage along with poor quality of life in Takayasu arteritis: cross-sectional results of a long-term followed-up multicentre cohort. Clin Exp Rheumatol 35(Suppl 103):77–82PubMed Omma A, Erer B, Karadag O et al (2017) Remarkable damage along with poor quality of life in Takayasu arteritis: cross-sectional results of a long-term followed-up multicentre cohort. Clin Exp Rheumatol 35(Suppl 103):77–82PubMed
206.
Zurück zum Zitat Patil P, Williams M, Maw WW et al (2015) Fast track pathway reduces sight loss in giant cell arteritis: results of a longitudinal observational cohort study. Clin Exp Rheumatol 33:103–106 Patil P, Williams M, Maw WW et al (2015) Fast track pathway reduces sight loss in giant cell arteritis: results of a longitudinal observational cohort study. Clin Exp Rheumatol 33:103–106
214.
Zurück zum Zitat Quartuccio L, Schiavon F, Zuliani F et al (2012) Long-term efficacy and improvement of health-related quality of life in patients with Takayasu’s arteritis treated with infliximab. Clin Exp Rheumatol 30:922–928PubMed Quartuccio L, Schiavon F, Zuliani F et al (2012) Long-term efficacy and improvement of health-related quality of life in patients with Takayasu’s arteritis treated with infliximab. Clin Exp Rheumatol 30:922–928PubMed
220.
226.
Zurück zum Zitat Sammel AM, Hsiao E, Schembri G et al (2019) Diagnostic accuracy of positron emission tomography/computed tomography of the head, neck, and chest for giant cell arteritis: a prospective, double-blind, cross-sectional study. Arthritis Rheumatol 71:1319–1328. https://doi.org/10.1002/art.40864CrossRefPubMed Sammel AM, Hsiao E, Schembri G et al (2019) Diagnostic accuracy of positron emission tomography/computed tomography of the head, neck, and chest for giant cell arteritis: a prospective, double-blind, cross-sectional study. Arthritis Rheumatol 71:1319–1328. https://​doi.​org/​10.​1002/​art.​40864CrossRefPubMed
230.
Zurück zum Zitat Schaufelberger C, Andersson R, Nordborg E (1998) No additive effect of cyclosporin a compared with glucocorticoid treatment alone in giant cell arteritis: results of an open, controlled, randomized study. Br J Rheumatol 37:464–465CrossRefPubMed Schaufelberger C, Andersson R, Nordborg E (1998) No additive effect of cyclosporin a compared with glucocorticoid treatment alone in giant cell arteritis: results of an open, controlled, randomized study. Br J Rheumatol 37:464–465CrossRefPubMed
232.
Zurück zum Zitat Schmidt D, Löffler KU (1994) Temporal arteritis. Comparison of histological and clinical findings. Acta Ophthalmol (Copenh) 72:319–325CrossRef Schmidt D, Löffler KU (1994) Temporal arteritis. Comparison of histological and clinical findings. Acta Ophthalmol (Copenh) 72:319–325CrossRef
233.
242.
Zurück zum Zitat Sharma BK, Jain S, Suri S, Numano F (1996) Diagnostic criteria for Takayasu arteritis. Int J Cardiol 54(Suppl):S141–S147CrossRefPubMed Sharma BK, Jain S, Suri S, Numano F (1996) Diagnostic criteria for Takayasu arteritis. Int J Cardiol 54(Suppl):S141–S147CrossRefPubMed
243.
Zurück zum Zitat Sharma BK, Siveski-Iliskovic N, Singal PK (1995) Takayasu arteritis may be underdiagnosed in North America. Can J Cardiol 11:311–316PubMed Sharma BK, Siveski-Iliskovic N, Singal PK (1995) Takayasu arteritis may be underdiagnosed in North America. Can J Cardiol 11:311–316PubMed
244.
Zurück zum Zitat Sharma S, Sharma S, Taneja K et al (1998) Morphological mural changes in the aorta in non-specific aortoarteritis (Takayasu’s arteritis): assessment by intravascular ultrasound imaging. Clin Radiol 53:37–43CrossRefPubMed Sharma S, Sharma S, Taneja K et al (1998) Morphological mural changes in the aorta in non-specific aortoarteritis (Takayasu’s arteritis): assessment by intravascular ultrasound imaging. Clin Radiol 53:37–43CrossRefPubMed
249.
Zurück zum Zitat de Souza AWS, Machado NP, Pereira VM et al (2010) Antiplatelet therapy for the prevention of arterial ischemic events in Takayasu arteritis. Circ J 74:1236–1241CrossRefPubMed de Souza AWS, Machado NP, Pereira VM et al (2010) Antiplatelet therapy for the prevention of arterial ischemic events in Takayasu arteritis. Circ J 74:1236–1241CrossRefPubMed
251.
Zurück zum Zitat Spiera RF, Mitnick HJ, Kupersmith M et al (2001) A prospective, double-blind, randomized, placebo controlled trial of methotrexate in the treatment of giant cell arteritis (GCA). Clin Exp Rheumatol 19:495–501PubMed Spiera RF, Mitnick HJ, Kupersmith M et al (2001) A prospective, double-blind, randomized, placebo controlled trial of methotrexate in the treatment of giant cell arteritis (GCA). Clin Exp Rheumatol 19:495–501PubMed
252.
Zurück zum Zitat Stone JH, Bao M, Han J et al (2019) Long-term outcome of Tocilizumab for patients with giant cell arteritis: results from part 2 of the GiACTA trial. Ann Rheum Dis 78(Suppl 2):A145 Stone JH, Bao M, Han J et al (2019) Long-term outcome of Tocilizumab for patients with giant cell arteritis: results from part 2 of the GiACTA trial. Ann Rheum Dis 78(Suppl 2):A145
261.
Zurück zum Zitat Uddhammar A, Eriksson A‑L, Nyström L et al (2002) Increased mortality due to cardiovascular disease in patients with giant cell arteritis in northern Sweden. J Rheumatol 29:737–742PubMed Uddhammar A, Eriksson A‑L, Nyström L et al (2002) Increased mortality due to cardiovascular disease in patients with giant cell arteritis in northern Sweden. J Rheumatol 29:737–742PubMed
262.
Zurück zum Zitat Valsakumar AK, Valappil UC, Jorapur V et al (2003) Role of immunosuppressive therapy on clinical, immunological, and angiographic outcome in active Takayasu’s arteritis. J Rheumatol 30:1793–1798PubMed Valsakumar AK, Valappil UC, Jorapur V et al (2003) Role of immunosuppressive therapy on clinical, immunological, and angiographic outcome in active Takayasu’s arteritis. J Rheumatol 30:1793–1798PubMed
265.
Zurück zum Zitat Warrington KJ, Weyand CM (2014) Giant cell arteritis and polymyalgia rheumatica. In: Ball GV, Fessler BJ, Bridges SL (Hrsg) Oxf. Textb. Vasc., 3. Aufl. Oxford University Press, Oxford, S 307–318CrossRef Warrington KJ, Weyand CM (2014) Giant cell arteritis and polymyalgia rheumatica. In: Ball GV, Fessler BJ, Bridges SL (Hrsg) Oxf. Textb. Vasc., 3. Aufl. Oxford University Press, Oxford, S 307–318CrossRef
274.
Zurück zum Zitat Yamada I, Nakagawa T, Himeno Y et al (2000) Takayasu arteritis: diagnosis with breath-hold contrast-enhanced three-dimensional MR angiography. J Magn Reson Imaging 11:481–487CrossRefPubMed Yamada I, Nakagawa T, Himeno Y et al (2000) Takayasu arteritis: diagnosis with breath-hold contrast-enhanced three-dimensional MR angiography. J Magn Reson Imaging 11:481–487CrossRefPubMed
279.
Zurück zum Zitat Zhou J, Chen Z, Li J et al (2017) The efficacy of tocilizumab for the treatment of Chinese Takayasu’s arteritis. Clin Exp Rheumatol 35(Suppl 103):171–175PubMed Zhou J, Chen Z, Li J et al (2017) The efficacy of tocilizumab for the treatment of Chinese Takayasu’s arteritis. Clin Exp Rheumatol 35(Suppl 103):171–175PubMed
Metadaten
Titel
S2k-Leitlinie: Management der Großgefäßvaskulitiden
verfasst von
Dr. J. H. Schirmer
P. M. Aries
K. Balzer
P. Berlit
T. A. Bley
F. Buttgereit
M. Czihal
C. Dechant
C. Dejaco
U. Garske
J. Henes
J. U. Holle
K. Holl-Ulrich
P. Lamprecht
B. Nölle
F. Moosig
J. Rech
K. Scheuermann
M. Schmalzing
W. A. Schmidt
M. Schneider
H. Schulze-Koops
N. Venhoff
P. M. Villiger
T. Witte
M. Zänker
Prof. Dr. B. Hellmich
Publikationsdatum
01.11.2020
Verlag
Springer Medizin
Erschienen in
Zeitschrift für Rheumatologie / Ausgabe Sonderheft 3/2020
Print ISSN: 0340-1855
Elektronische ISSN: 1435-1250
DOI
https://doi.org/10.1007/s00393-020-00893-1

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.